title: Central retinal vein occlusion following infliximab treatment for plaque-type psoriasis.
authors.forename: Theognosia
authors.initials: T
authors.lastname: Vergou
authors.forename: Aikaterini E
authors.initials: AE
authors.lastname: Moustou
authors.forename: Apostolos
authors.initials: A
authors.lastname: Maniateas
authors.forename: Alexander J
authors.initials: AJ
authors.lastname: Stratigos
authors.forename: Andreas
authors.initials: A
authors.lastname: Katsambas
authors.forename: Christina
authors.initials: C
authors.lastname: Antoniou
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects*; D003879:Dermatologic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D005451:Fluorescein Angiography; D006801:Humans; D006949:Hyperlipidemias; D000069285:Infliximab; D008297:Male; D008875:Middle Aged; D009887:Ophthalmoscopy; D011565:Psoriasis / Q000188:drug therapy; D012170:Retinal Vein Occlusion / Q000139:chemically induced* / Q000175:diagnosis; D012907:Smoking; D041623:Tomography, Optical Coherence
chemical_list: D000911:Antibodies, Monoclonal; D003879:Dermatologic Agents; D000069285:Infliximab